ClinicalTrials.gg
CompletedNCT05984641Updated Apr 3, 2024

Efficacy and Safety of CONAN® Proctological Cream for Treatment of Haemorrhoidal Disease

An interventional study of CONAN® Proctological Cream in Hemorrhoid Pain and Haemorrhoid Inflammation, sponsored by Omikron Italia S.r.l.. Completed at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Omikron Italia S.r.l. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Mar 2022, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hemorrhoids with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Hemorrhoids · Italy.

Enrollment
11th of 11
40 · median 105
Started
2022
the only one that year
No phase
5 of 15
none open now
Registered
11th of 15
by date
Lead sponsor
1 of 15
Omikron Italia S.r.l.

Among the 15 studies in Hemorrhoids with a site in Italy, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 5 with no phase, and was the 11th registered.

Hemorrhoids

240 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

Browse Hemorrhoids studies →

Open to participants now

3 of the 15 studies in Hemorrhoids with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 38 Hemorrhoids studies recruiting now, 15 (39%) set no upper age limit and 11 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hemorrhoids with a site in Italy, or all of them as a file.
02

Study summary

Aim of the study is to assess the efficacy, safety and tolerability of CONAN® (Proctological Cream, Medical Device, Omikron Italia Srl) on most frequent symptoms in grade 1-2 of haemorrhoidal disease and anal fissures.

Read the detailed description

Background: To evaluate the role of CONAN® Proctological Cream containing escin, hesperidin and hyaluronic acid in topical treatment of haemorrhoidal disease and anal fissures and its potential efficacy in reducing related symptoms.

Methods: Forty patients with haemorrhoidal disease and anal fissures were enrolled. Of them, 20 were randomized to receive the medical device CONAN® Cream (Group A) and 20 to the untreated control group (Group B). At each scheduled visit, total symptoms were assessed and recorded by assigning a Numerical Rating Scale score from 0 to 10. The adverse events reported by study subjects were also assessed and recorded.

03

Conditions studied

  • Hemorrhoid Pain
  • Haemorrhoid Inflammation

Keywords

  • Haemorrhoids; anal fissures; controlled clinical trial.
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 70 years
  • Hemorrhoidal pathology, anal fissures and anitis
  • NRS score ≥ 3 for at least one of the symptoms (burning, itching, feeling of heaviness, foreign body)

Exclusion criteria

Exclusion Criteria:

  • Known to study products
  • Proctitis
  • Current therapy with other local treatments based on phlebotropes and/or anti-inflammatories
  • Surgical treatments undergone less than a year after inclusion
  • Pregnancy, breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Group A

    Active treatment CONAN® (Medical Device, Omikron Italia Srl) a proctological cream containing 2.5% glycerin macerate from horse chestnut buds (escin), 1% hesperidin, 0.1% hyaluronic acid, 0.1% centella asiatica and 2.5% glycerinic extract of mallow; Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.

    Device: CONAN® Proctological Cream

  • No intervention
    Group B

    No intervention. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.

Interventions

  • DeviceCONAN® Proctological Cream

    The active treatment samples used for the duration of the study were allocated at the site involved and consisted in 30 g tubes with an endorectal applicator, identified by the batch number, expiry date and information on the study on dedicated labels. The treatment of patients randomized to Group A consisted in applying the local treatment (1 application 3 times/day) for 30 days. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.

06

What researchers measure

Primary outcomes

  1. Change in the symptom numerical rating scale

    The primary outcome was the change in the symptom numerical rating scale (NRS) score after one month (V3) of treatment compared to the baseline in the two groups.

    Time frame: 30 days

Secondary outcomes

  1. Evaluation of potential adverse events and treatment compliance

    The safety of the treatment was investigated by recording and systemic and local adverse events such as systemic allergic reactions, skin sensitisation and discomfort, etc. Treatment compliance was evaluated through assessment by the investigator of the empty study treatment cream tubes returned by patients at the end of the study.

    Time frame: 30 days

07

Study locations

1 site
  • Policlinico Tor Vergata Foundation (PTV)
    Rome, 00133, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Aug 2022, 5 months.

Of 72 interventional studies with no phase under Hemorrhoids, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2023
First posted
Aug 9, 2023
StartActual
Mar 1, 2022
Primary completionActual
Aug 29, 2022
CompletionActual
Sep 30, 2022
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05984641
Lead sponsor
Omikron Italia S.r.l.
Responsible party
Sponsor
First posted
Aug 9, 2023
Start date
Mar 1, 2022
Primary completion
Aug 29, 2022
Completion
Sep 30, 2022
Last update
Apr 3, 2024

Study contacts

Nicola Di Lorenzo, Medicine
principal investigator · Department of Surgical Sciences,University of Tor Vergata, Policlinico Tor Vergata
Gabriella Giarratano, Medicine
study chair · Department of Surgical Sciences,University of Tor Vergata, Policlinico Tor Vergata

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion